Exploring VEGF-C and -D Inhibition

Timothy L. Jackson, PhD, MB ChB, FRCOphth

Show Description +

Dr. Jackson examines the current data for sozinibercept (OPT-302, Ophthea), an investigational VEGF-C and -D inhibitor, for the treatment of AMD.

Posted: 9/26/2024

Keywords:

retina-meeting-recap

•

Anti-VEGF

•

VEGF-C

•

VEGF-D

•

sozinibercept

•

Ophthea

•

Age-Related Macular Degeneration (AMD)

•

OPT-302

Up Next

Name: Exploring VEGF-C and -D Inhibition
Uploaded: 2024-09-26T18:09:44+00:00
Description: Dr. Jackson examines the current data for sozinibercept (OPT-302, Ophthea), an investigational VEGF-C and -D inhibitor, for the treatment of AMD.

The Clinical Benefits of the PDS

Patricia Udaondo, MD

RD Repair: Why Slower Reattachment is Better

Stratos V. Gotzaridis, MBBS, MD

Today's Approaches to Myopic Neovascularization

Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI

Anti-VEGF for ROP: Efficacy and Safety Outcomes

Andreas Stahl, MD

Advancing Research Methodology in Retina

Varun Chaudhary, MD, FRCS(C)

The Clinical Challenges of AAV Vectors

Kanmin Xue, PhD, MA, MB, BChir, FRCOphth

Plasma Kallikrein Inhibition: A Novel Approach to DME

Arshad Khanani, MD, MA, FASRS

Next-Gen Therapies for AMD and DME

Nicole Eter, MD

The Role of Anti-VEGF Therapy in Diabetic Vitreous Hemorrhage

David Steel, MD, MBBS, FRCOphth

Exploring VEGF-C and -D Inhibition

Timothy L. Jackson, PhD, MB ChB, FRCOphth

Back to All Videos

Exploring VEGF-C and -D Inhibition

Timothy L. Jackson, PhD, MB ChB, FRCOphth

Dr. Jackson examines the current data for sozinibercept (OPT-302, Ophthea), an investigational VEGF-C and -D inhibitor, for the treatment of AMD.

Posted: 9/26/2024

Keywords:

retina-meeting-recap

•

Anti-VEGF

•

VEGF-C

•

VEGF-D

•

sozinibercept

•

Ophthea

•

Age-Related Macular Degeneration (AMD)

•

OPT-302

Please log in to leave a comment.

Meeting Coverage:

EURETINA Congress

Exploring VEGF-C and -D Inhibition

Up Next

Exploring VEGF-C and -D Inhibition

More From EURETINA: 2024 Coverage